Co-Diagnostics
CODX
59 hedge funds and large institutions have $14.8M invested in Co-Diagnostics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 22 reducing their positions, and 12 closing their positions.
133% more call options, than puts
Call options by funds: $1.23M | Put options by funds: $526K
0.59% more ownership
Funds ownership: 18.4% → 18.99% (+0.59%)
9% less funds holding
Funds holding: 65 → 59 (-6)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
45% less capital inflows, than outflows
Capital inflows: $1.29M | Capital outflows: $2.36M
50% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$552K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$236K |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$82.9K |
| 4 |
Koss-Olinger Consulting
Gainesville,
Florida
|
+$82.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$71.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$441K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$222K |
| 3 |
D.E. Shaw & Co
New York
|
-$183K |
| 4 |
Bank of New York Mellon
New York
|
-$167K |
| 5 |
Renaissance Technologies
New York
|
-$158K |
CODX Hedge Fund Activity: Q4 2022 in Review
59 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2022, worth a combined $14.8M — down 26% from $20M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CODX and 8 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 11 added.
The largest buyer was Vanguard Group, adding an estimated $552K. The largest seller was Walleye Capital, exiting entirely with an estimated $441K sold.
- 59 institutional investors held Co-Diagnostics (CODX) as of Q4 2022, down from 65 in Q3 2022.
- Funds reported $14.8M of Co-Diagnostics stock for Q4 2022, down 26% quarter-over-quarter.
- 8 funds opened new Co-Diagnostics positions in Q4 2022 and 12 closed out, a net change of -4 holders.
- The largest Co-Diagnostics buyer in Q4 2022 was Vanguard Group, an estimated $552K added.
- The largest Co-Diagnostics seller in Q4 2022 was Walleye Capital, an estimated $441K sold.
Based on aggregated 13F filings for Q4 2022.